After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...

Usually described as a splitting or multiple personality disorder, the concept of schizophrenia is not entirely but rather a ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030.

As per the Brain and Behavior Research Foundation, it combines two compounds called xanomeline and trospium chloride. This is ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator instructions] Today's call is also being ...

With no drugs with different mechanisms for schizophrenia for ... i.e. both positive (delusions and hallucination) symptoms and negative (social withdrawal and apathy). Emraclidine, meanwhile ...

Shares in AbbVie have slumped after a pair of failed phase 2 trials for emraclidine, a schizophrenia drug ... measured using the Positive and Negative Syndrome Scale (PANSS) total score.

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Legend Biotech Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Using diagnostic labels for people with mental health issues is on the rise, but this can sometimes hinder rather than help, psychologists warn.

We recently published a list of 15 Stocks ChatGPT Predicts Could Make You Wealthy in 10 Years. In this article, we are going ...